Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:30:16 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Z:IGC - IGC PHARMA INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IGC - Z0.10.2951·0.30310.40.2973-0.0021-0.7825.32109390.2926  0.30  0.29130.4985  0.24211:12:4908:3015 min RT 2¢

Recent Trades - Last 10 of 939
Time ETExPriceChangeVolume
11:12:49Z0.2973-0.0021500
11:12:19Z0.2973-0.0021200
11:11:43Z0.2973-0.00176
11:11:43Z0.2973-0.00172
11:10:15Z0.2973-0.00172
11:10:15Z0.2973-0.00176
11:10:15Z0.2973-0.001710
11:08:25Z0.2973-0.00178
11:08:25Z0.2973-0.00172
11:07:13Z0.2951-0.00432,583

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-09 08:30U:IGCNews ReleaseAscendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
2026-06-02 08:30U:IGCNews ReleaseIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
2026-05-19 17:30U:IGCNews ReleaseIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
2026-05-15 08:00U:IGCNews ReleaseIGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
2026-04-28 12:15U:IGCNews ReleaseIGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
2026-04-22 08:30U:IGCNews ReleaseIGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
2026-04-20 08:30U:IGCNews ReleaseIGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
2026-04-14 08:30U:IGCNews ReleaseIGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
2026-04-08 12:45U:IGCNews ReleaseAscendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
2026-04-07 08:00U:IGCNews ReleaseIGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
2026-03-30 08:00U:IGCNews ReleaseIGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
2026-03-19 09:00U:IGCNews ReleaseIGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
2026-03-18 09:00U:IGCNews ReleaseIGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
2026-02-26 08:30U:IGCNews ReleaseIGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
2026-02-24 08:30U:IGCNews ReleaseIGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
2026-02-23 08:30U:IGCNews ReleaseIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
2026-02-17 08:30U:IGCNews ReleaseIGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
2026-02-12 08:30U:IGCNews ReleaseIGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
2026-02-10 08:30U:IGCNews ReleaseIGC Pharma Announces Equity Research Update by Alliance Global Partners
2026-02-09 08:30U:IGCNews ReleaseIGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center